@article{dd6ac17e732d4f81b016c1d2311d6af5,
title = "Trials, Tribunals, and Opportunities for Lung Cancer KRASG12C Brain Metastases",
abstract = "The activity ofKRAS inhibitors against brainmetastases is relatively unexplored. The recent work on preclinical models and preliminary data from the ongoing KRYSTAL-1 phase Ib clinical trial support the potential of adagrasib (MRTX849) to penetrate the central nervous system and provide control of KRASG12C brain metastases.",
author = "Anuhya Kommalapati and Mansfield, {Aaron S.}",
note = "Funding Information: A.S. Mansfield reports grants and other support from Bristol-Myers Squibb; grants from Novartis and Verily; other support from Rising Tide, Triptych Health Partners Expert Think Tank, Janssen, BeiGene, Chugai Pharmaceutical (Roche), Ideology Health, Miami International Mesothelioma Symposium (presenter), AXIS Medical Education (CME presenter), Johnson & Johnson Global Services, Intellisphere (CME presenter), Answers in CME, Roche, and Antoni van Leeuwenhoek Kanker Instituut (CME presenter); and participation on advisory boards for AbbVie, AstraZeneca, Bristol-Myers Squibb, and Genentech/Roche outside the submitted work. In addition, A.S. Mansfield has served as a non-remunerated director of Mesothelioma Applied Research Foundation. No disclosures were reported by the other author. Publisher Copyright: {\textcopyright} 2022 American Association for Cancer Research.",
year = "2022",
month = aug,
day = "1",
doi = "10.1158/1078-0432.CCR-22-1137",
language = "English (US)",
volume = "28",
pages = "3179--3181",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "15",
}